Stockreport

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update [Yahoo! Finance]

Foghorn Therapeutics Inc.  (FHTX) 
PDF IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) selective inhibitor; Phase 1 trial planned to begin in the second half of 2024 with primary target [Read more]